Arrowhead Pharma Stock Price, News & Analysis

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has achieved a $30 million milestone from GSK (LSE/NYSE: GSK) following the initiation of GSK4532990's Phase 2b trial for treating non-alcoholic steatohepatitis (NASH). This investigational RNA interference therapeutic was licensed to GSK in November 2021, with Arrowhead retaining rights for Greater China. The trial, known as HORIZON (NCT05583344), will assess the drug's efficacy and safety in up to 246 participants with pre-cirrhotic NASH. GSK4532990 targets HSD17B13, a gene linked to metabolic protection against NASH.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced on March 29, 2023, that its Compensation Committee approved inducement grants for 31 new employees, totaling up to 46,050 restricted stock units. These grants, which incentivize new hires, are outside the company’s stockholder-approved equity incentive plans and will vest over four years. Arrowhead specializes in developing RNA interference-based therapeutics that target intractable diseases by silencing specific genes. This strategic move aims to attract talent to enhance its research and development efforts in RNAi-based medicines.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has received Fast Track designation from the FDA for its investigational therapy ARO-APOC3, aimed at reducing triglycerides in patients with familial chylomicronemia syndrome (FCS). This designation facilitates a faster development process and offers benefits such as priority review and accelerated approval. ARO-APOC3 targets apolipoprotein C-III (APOC3) and is currently being assessed in multiple clinical trials, including Phase 3 and Phase 2 studies for FCS and other conditions. There are currently no approved therapies for FCS, underscoring the significance of this treatment.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is set to participate in the respiratory/infections panel discussion at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 10:30 a.m. ET, in Boston. The event will be accessible via a webcast on their Investors page. Arrowhead specializes in developing RNA interference therapeutics targeting intractable diseases, utilizing innovative RNA chemistries for gene silencing.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced interim results from Part 1 of the AROC3-1001 Phase 1/2 clinical study of ARO-C3, an RNA interference therapeutic aimed at reducing complement component 3 (C3) in patients with various complement-mediated diseases. The interim results showed a mean reduction of 88% in serum C3 and 91% in AH50 at the highest dose. The study indicated safety and tolerability, with no significant adverse events reported. Dosing for Part 2 is expected to start in the first half of 2023. The company aims to address unmet medical needs in conditions like IgA nephropathy and C3 glomerulopathy.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its acquisition of rights to ARO-PNPLA3, an investigational RNA interference therapy for non-alcoholic steatohepatitis (NASH). This therapy showed an impressive up to 40% mean reduction in liver fat in homozygous patients after a single dose in a Phase 1 clinical study, with no significant adverse effects reported. This clinical development is timely, as NASH has no FDA-approved treatments. The acquisition comes following Janssen Pharmaceuticals' decision to return the rights after a strategic review. Arrowhead plans further studies and data communications for ARO-PNPLA3.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported a fiscal Q1 2023 net loss of $41.3 million, or $0.39 per diluted share, a reduction from a net loss of $62.9 million in Q1 2022. Revenue increased to $62.5 million, compared to $27.4 million the previous year. The company achieved significant milestones, earning $40 million from Amgen and Horizon Therapeutics. A Phase 2 SEQUOIA study showed fibrosis regression in 50% of patients treated with investigational fazirsiran. The company's cash, cash equivalents, and investments totaled $617.6 million as of December 31, 2022, up from $482.3 million at September 30, 2022.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated a Phase 1/2a clinical trial for ARO-MMP7, targeting matrix metalloproteinase 7 (MMP7) to treat idiopathic pulmonary fibrosis (IPF). The trial, AROMMP7-1001, will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in up to 56 healthy volunteers and 21 IPF patients. MMP7 is implicated in IPF's progression, causing inflammation and fibrosis. The trial’s results could address the significant unmet medical need for IPF patients, aiming to enhance lung function beyond current therapies. The ongoing research may position Arrowhead favorably in the competitive biotech landscape.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter, ending December 31, 2022. Investors can access the live audio webcast on the company's website, and a replay will be available shortly after. The call will cover the company's progress in developing medicines that target intractable diseases through RNA interference (RNAi), which silences genes responsible for these conditions.